Navitoclax
About
About Navitoclax
Navitoclax (ABT-263) is a BCL-2/BCL-xL inhibitor originally developed as a cancer therapeutic that has demonstrated potent senolytic activity in preclinical aging models, extending lifespan and improving physical function in aged mice. Its clinical use in oncology is limited by platelet toxicity, but intermittent low-dose longevity protocols are being investigated to harness senolytic benefits while minimizing hematological side effects.
Science
Mechanism of Action
Directly inhibits BCL-2 and BCL-xL anti-apoptotic proteins that senescent cells abnormally upregulate as part of their senescence-associated anti-apoptotic program, restoring apoptosis sensitivity and enabling selective senescent cell clearance.
Dosing
Typical Protocol
Not established for longevity use; oncology doses are 150–325 mg daily. Intermittent protocols are experimental and physician-supervised only.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.
Find a Verified Provider
See which Vial-verified providers offer Navitoclax — with trust scores, legal credentials, and pricing transparency.